A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)-Science-Chemical Encyclopedia-lookchem

A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)
Add time:08/24/2019 Source:sciencedirect.com

ObjectiveEvaluate safety/tolerability/efficacy of MK-8242 in subjects with refractory/recurrent AML.

We also recommend Trading Suppliers and Manufacturers of MK 287 (cas 135947-75-0). Pls Click Website Link as below: cas 135947-75-0 suppliers

Prev:Research PapersStandardization and Identification of Minor Components of Silymarin (MK-001)
Next: Original articleBupivacaine-induced convulsion is suppressed by MK-801)

Click to view details

Health and Chemicalmore >